

DRAFT Medical Coverage Policy | Genetic Testing for Inherited Thrombophilia



EFFECTIVE DATE: 06|01|2024

POLICY LAST REVIEWED: 03|06|2024

OVERVIEW

Inherited thrombophilias are a group of disorders that predispose individuals to thrombosis. Genetic testing is available for some of these disorders and could assist in the diagnosis and/or management of patients with thrombosis. For example, testing is available for types of inherited thrombophilia, including variants in the 5,10-methylenetetrahydrofolate reductase (MTHFR) gene, the factor V gene (factor V Leiden [FVL] variant), and the prothrombin (factor II) gene.

MEDICAL CRITERIA

Not applicable

PRIOR AUTHORIZATION

Not applicable

POLICY STATEMENT

Medicare Advantage Plans

Genetic testing for inherited thrombophilia, including testing for the *factor V Leiden* variant, prothrombin (factor II) gene variants, and variants in the 5,10-methylenetetrahydrofolate reductase (*MTHFR*) gene, is not covered as the evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Commercial Products

Genetic testing for inherited thrombophilia, including testing for the *factor V Leiden* variant, prothrombin (factor II) gene variants, and variants in the 5,10-methylenetetrahydrofolate reductase (*MTHFR*) gene, is not medically necessary as the evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

COVERAGE

Benefits may vary between groups/contracts. Please refer to the Evidence of Coverage or Subscriber Agreement for applicable not medically necessary/not covered benefits/coverage.

BACKGROUND

The overall U.S. incidence of venous thromboembolism (VTE) is approximately 1 per 1,000 person-years, and the lifetime clinical prevalence is approximately 5%, accounting for 100,000 deaths annually. The risk is strongly age-related, with the greatest risk in older populations. Venous thromboembolism also recurs frequently; the estimated cumulative incidence of first VTE recurrence is 30% at 10 years. These figures do not separate patients with known predisposing conditions from those without.

Risk factors for thrombosis include clinical and demographic variables, and at least 1 risk factor can be identified in approximately 80% of patients with thrombosis. The following list includes the most important risk factors:

- Malignancy
- Immobility
- Surgery

- Obesity
- Pregnancy
- Hormonal therapy such as estrogen/progestin or selective estrogen modulator products
- Systemic lupus erythematosus and/or other rheumatologic disorders
- Myeloproliferative disorders
- Liver dysfunction
- Nephrotic syndrome
- Hereditary factors.

Pregnancy often is considered a special circumstance because of its frequency and unique considerations for preventing and treating VTE. Pregnancy is associated with a 5- to 10-fold increase in VTE risk, and absolute VTE risk in pregnancy is estimated to be 1 to 2 per 1000 deliveries.² In women with a history of pregnancy-related VTE, risk of recurrent VTE with subsequent pregnancies is increased greatly at approximately 100-fold.

Treatment

Treatment of thrombosis involves anticoagulation for a minimum of 3 to 6 months. After this initial treatment period, patients deemed to be at a continued high risk for recurrent thrombosis may continue on anticoagulation therapy for longer periods, sometimes indefinitely. Anticoagulation is effective for reducing the subsequent risk of thrombosis but carries its own risk of bleeding.

Inherited Thrombophilia

Inherited thrombophilias are a group of clinical conditions characterized by genetic variant defects associated with a change in the amount or function of a protein in the coagulation system and a predisposition to thrombosis. Not all individuals with a genetic predisposition to thrombosis will develop VTE. The presence of inherited thrombophilia will presumably interact with other VTE risk factors to determine an individual's VTE risk.

A number of conditions fall under the classification of inherited thrombophilias. Inherited thrombophilias include the following conditions, which are defined by defects in the coagulation cascade:

- Activated protein C resistance (factor V Leiden [FVL] variant)
- Prothrombin (*factor II*) gene variant (G20210A)
- Protein C deficiency
- Protein S deficiency
- Prothrombin deficiency
- Hyper-homocysteinemia (5,10-methylenetetrahydrofolate reductase [*MTHFR*] variant).

The most common type of inherited thrombophilia is FVL, which accounts for up to 50% of inherited thrombophilia syndromes. Generally, routine testing for hypercoagulable disorders is not recommended in unselected patients.³ For those considered at risk (eg, strong family history, recurrent thromboses), the prevalence of identifying an inherited thrombophilia ranges from 5% to 40%; the prevalence is estimated at 12% to 40% for FVL and 6% to 18% for prothrombin G20210A variant in this population.

Genetic Testing

Genetic testing for gene variants associated with thrombophilias is available for FVL, the prothrombin G20210A variant, and *MTHFR*. Genetic testing for inherited thrombophilia can be considered in several clinical situations. Clinical situations addressed herein include the following:

- Assessment of thrombosis risk in asymptomatic patients (screening for inherited thrombophilia)
- Evaluation of a patient with established thrombosis, for consideration of a change in anticoagulant management based on results
- Evaluation of close relatives of patients with documented inherited thrombophilia or with a clinical and family history consistent with an inherited thrombophilia

- Evaluation of patients in other situations who are considered at high-risk for thrombosis (eg, pregnancy, planned major surgery, exogenous hormone use).

For individuals who are asymptomatic with or without a personal or family history of venous thromboembolism (VTE) or who are asymptomatic with increased VTE risk (eg, due to pregnancy) who receive genetic testing for variants in *MTHFR*, or genetic testing for coagulation factor V and coagulation factor II, the evidence includes a large randomized controlled trial (RCT), prospective cohort analyses, retrospective family studies, case-control studies, and meta-analyses. Relevant outcomes are morbid events and treatment-related morbidity. The clinical validity of genetic testing has been demonstrated by the presence of an FVL variant or a prothrombin gene variant, and an association with an increased risk for subsequent VTE across various populations studied. However, the magnitude of the association is relatively modest, with odds ratios most commonly between 1 and 2, except for family members of individuals with inherited thrombophilia, for whom odds ratios are somewhat higher. The clinical utility of testing for FVL or prothrombin variants has not been demonstrated. Although the presence of inherited thrombophilia increases the risk for subsequent VTE events, the increase is modest, and the absolute risk of thrombosis remains low. Available prophylactic treatments (eg, anticoagulation) have defined risks of major bleeding and other adverse events that may outweigh the reduction in VTE and therefore result in net harm. Currently, available evidence has not defined a role for thrombophilia testing for decisions on initiation of prophylactic anticoagulation or the length of anticoagulation treatment. For *MTHFR* testing, clinical validity and clinical utility of genetic testing are uncertain. Because clinical utility of testing for elevated serum homocysteine itself has not been established, the utility of genetic testing also has not been established. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

CODING

Medicare Advantage Plans and Commercial Products

The following code(s) are not covered for Medicare Advantage Plans and not medically necessary for Commercial Products:

- 81240** F2 (prothrombin, coagulation factor II) (eg, hereditary hypercoagulability) gene analysis, 20210G>A variant
- 81241** F5 (coagulation Factor V) (eg, hereditary hypercoagulability) gene analysis, Leiden variant
- 81291** MTHFR (5, 10-methylenetetrahydrofolate reductase) (eg, hereditary hypercoagulability) gene analysis, common variants (eg, 677T, 1298C)

RELATED POLICIES

Genetic Testing Services

PUBLISHED

Provider Update, April 2024

REFERENCES

1. Heit JA, Silverstein MD, Mohr DN, et al. The epidemiology of venous thromboembolism in the community. *Thromb Haemost.* Jul 2001; 86(1): 452-63. PMID 11487036
2. Baglin T, Gray E, Greaves M, et al. Clinical guidelines for testing for heritable thrombophilia. *Br J Haematol.* Apr 2010; 149(2): 209-20. PMID 20128794
3. Bauer KA, Lip GYH. Evaluating adult patients with established venous thromboembolism for acquired and inherited risk factors In: Leung LLK, Mandel J, eds. *UpToDate*. Waltham, MA: UpToDate; 2022.
4. American College of Obstetricians and Gynecologists Women's Health Care Physicians. ACOG Practice Bulletin No. 138: Inherited thrombophilias in pregnancy. *Obstet Gynecol.* Sep 2013; 122(3): 706-17. PMID 23963422
5. Russo PD, Damante G, Pasca S, et al. Thrombophilic mutations as risk factor for retinal vein occlusion: a case-control study. *Clin Appl Thromb Hemost.* May 2015; 21(4): 373-7. PMID 24569626

6. Supanc V, Sonicki Z, Vukasovic I, et al. The role of classic risk factors and prothrombotic factor gene mutations in ischemic stroke risk development in young and middle-aged individuals. *J Stroke Cerebrovasc Dis*. Mar 2014; 23(3): e171-6. PMID 24189452
7. Zhou X, Qian W, Li J, et al. Who are at risk for thromboembolism after arthroplasty? A systematic review and meta-analysis. *Thromb Res*. Nov 2013; 132(5): 531-6. PMID 24074702
8. Li P, Qin C. Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and susceptibility to ischemic stroke: a meta-analysis. *Gene*. Feb 10 2014; 535(2): 359-64. PMID 24140489
9. Bezemer ID, Doggen CJ, Vos HL, et al. No association between the common MTHFR 677C- T polymorphism and venous thrombosis: results from the MEGA study. *Arch Intern Med*. Mar 12 2007; 167(5): 497-501. PMID 17353498
10. Joachim E, Goldenberg NA, Bernard TJ, et al. The methylenetetrahydrofolate reductase polymorphism (MTHFR c.677C T) and elevated plasma homocysteine levels in a U.S. pediatric population with incident thromboembolism. *Thromb Res*. Aug 2013; 132(2): 170-4. PMID 23866722
11. Chatterjee T, Gupta N, Choudhry VP, et al. Prediction of ischemic stroke in young Indians: is thrombophilia profiling a way out?. *Blood Coagul Fibrinolysis*. Jun 2013; 24(4): 449-53. PMID 23337710
12. den Heijer M, Willems HP, Blom HJ, et al. Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: A randomized, placebo-controlled, double-blind trial. *Blood*. Jan 01 2007; 109(1): 139-44. PMID 16960155
13. Gao M, Feng N, Zhang M, et al. Meta-analysis of the relationship between methylenetetrahydrofolate reductase C677T and A1298C polymorphism and venous thromboembolism in the Caucasian and Asian. *Biosci Rep*. Jul 31 2020; 40(7). PMID 32614041
14. Middeldorp S, Henkens CM, Koopman MM, et al. The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis. *Ann Intern Med*. Jan 01 1998; 128(1): 15-20. PMID 9424976
15. Kujovich JL. Prothrombin-Related Thrombophilia. In: Adam MP, Ardinger HH, Pagon RA, et al., eds. *GeneReviews*. Seattle, WA: University of Washington; 2022.
16. Gohil R, Peck G, Sharma P. The genetics of venous thromboembolism. A meta-analysis involving approximately 120,000 cases and 180,000 controls. *Thromb Haemost*. Aug 2009; 102(2): 360-70. PMID 19652888
17. Segal JB, Brotman DJ, Emadi A, et al. Outcomes of genetic testing in adults with a history of venous thromboembolism (Evidence Reports/Technology Assessment, No. 180). Rockville, MD: Agency for Healthcare Research and Quality; 2009.
18. Christiansen SC, Cannegieter SC, Koster T, et al. Thrombophilia, clinical factors, and recurrent venous thrombotic events. *JAMA*. May 18 2005; 293(19): 2352-61. PMID 15900005
19. Kearon C, Julian JA, Kovacs MJ, et al. Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial. *Blood*. Dec 01 2008; 112(12): 4432-6. PMID 18791166
20. Lijfering WM, Brouwer JL, Veeger NJ, et al. Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relatives. *Blood*. May 21 2009; 113(21): 5314-22. PMID 19139080
21. Prüller F, Weiss EC, Raggam RB, et al. Activated protein C resistance assay and factor V Leiden. *N Engl J Med*. Aug 14 2014; 371(7): 685-6. PMID 25119624
22. Coppens M, Reijnders JH, Middeldorp S, et al. Testing for inherited thrombophilia does not reduce the recurrence of venous thrombosis. *J Thromb Haemost*. Sep 2008; 6(9): 1474-7. PMID 18540999
23. Mahajerin A, Obasaju P, Eckert G, et al. Thrombophilia testing in children: a 7 year experience. *Pediatr Blood Cancer*. Mar 2014; 61(3): 523-7. PMID 24249220
24. Hindorff LA, Burke W, Laberge AM, et al. Motivating factors for physician ordering of factor V Leiden genetic tests. *Arch Intern Med*. Jan 12 2009; 169(1): 68-74. PMID 19139326
25. Press RD, Bauer KA, Kujovich JL, et al. Clinical utility of factor V Leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders. *Arch Pathol Lab Med*. Nov 2002; 126(11): 1304-18. PMID 12421138

26. Bradley LA, Palomaki GE, Bienstock J, et al. Can Factor V Leiden and prothrombin G20210A testing in women with recurrent pregnancy loss result in improved pregnancy outcomes?: Results from a targeted evidence-based review. *Genet Med.* Jan 2012; 14(1): 39-50. PMID 22237430
27. Liu X, Chen Y, Ye C, et al. Hereditary thrombophilia and recurrent pregnancy loss: a systematic review and meta-analysis. *Hum Reprod.* Apr 20 2021; 36(5): 1213-1229. PMID 33575779
28. Vandenbroucke JP, Koster T, Briët E, et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. *Lancet.* Nov 26 1994; 344(8935): 1453-7. PMID 7968118
29. Clark P, Walker ID, Langhorne P, et al. SPIN (Scottish Pregnancy Intervention) study: a multicenter, randomized controlled trial of low-molecular-weight heparin and low-dose aspirin in women with recurrent miscarriage. *Blood.* May 27 2010; 115(21): 4162-7. PMID 20237316
30. Kaandorp SP, Goddijn M, van der Post JA, et al. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. *N Engl J Med.* Apr 29 2010; 362(17): 1586-96. PMID 20335572
31. Skeith L, Carrier M, Kaaja R, et al. A meta-analysis of low-molecular-weight heparin to prevent pregnancy loss in women with inherited thrombophilia. *Blood.* Mar 31 2016; 127(13): 1650-5. PMID 26837697
32. de Jong PG, Kaandorp S, Di Nisio M, et al. Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia. *Cochrane Database Syst Rev.* Jul 04 2014; 2014(7): CD004734. PMID 24995856
33. Silver RM, Saade GR, Thorsten V, et al. Factor V Leiden, prothrombin G20210A, and methylene tetrahydrofolate reductase mutations and stillbirth: the Stillbirth Collaborative Research Network. *Am J Obstet Gynecol.* Oct 2016; 215(4): 468.e1-468.e17. PMID 27131585
34. Rodger MA, Hague WM, Kingdom J, et al. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. *Lancet.* Nov 08 2014; 384(9955): 1673-83. PMID 25066248
35. American Board of Internal Medicine Foundation. *Choosing Wisely.* 2021; <http://www.choosingwisely.org/>. Accessed March 29, 2023.
36. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. *Chest.* Feb 2016; 149(2): 315-352. PMID 26867832
37. Guyatt GH, Akl EA, Crowther M, et al. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest.* Feb 2012; 141(2 Suppl): 7S-47S. PMID 22315257
38. Stevens SM, Woller SC, Kreuziger LB, et al. Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. *Chest.* Dec 2021; 160(6): e545-e608. PMID 34352278
39. Hirsh J, Guyatt G, Albers GW, et al. Antithrombotic and thrombolytic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest.* Jun 2008; 133(6 Suppl): 110S-112S. PMID 18574260
40. Zhang S, Taylor AK, Huang X, et al. Venous thromboembolism laboratory testing (factor V Leiden and factor II c.*97G A), 2018 update: a technical standard of the American College of Medical Genetics and Genomics (ACMG). *Genet Med.* Dec 2018; 20(12): 1489-1498. PMID 30297698
41. De Stefano V, Rossi E. Testing for inherited thrombophilia and consequences for antithrombotic prophylaxis in patients with venous thromboembolism and their relatives. A review of the Guidelines from Scientific Societies and Working Groups. *Thromb Haemost.* Oct 2013; 110(4): 697-705. PMID 23846575
42. Metz TD, Silverman NS. ACOG Practice Bulletin No. 197: Inherited Thrombophilias in Pregnancy. *Obstet Gynecol.* Jul 2018; 132(1): e18-e34. PMID 29939939
43. Stevens SM, Woller SC, Bauer KA, et al. Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. *J Thromb Thrombolysis.* Jan 2016; 41(1): 154-64. PMID 26780744
44. Berg AO, Botkin J, Calonge N, et al. Recommendations from the EGAPP Working Group: routine testing for Factor V Leiden (R506Q) and prothrombin (20210G A) mutations in adults with a history of idiopathic venous thromboembolism and their adult family members. *Genet Med.* Jan 2011; 13(1): 67-76. PMID 21150787

DRAFT

CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

